12:00 AM
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RP6530: Phase I started

Rhizen began an open-label, dose-escalation, Italian Phase I trial to evaluate twice-daily oral RP6530 in up to 42 patients.

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >